Giannis Mountzios· @g_mountzios · X·· 23 小时前评分45
正文 · 机器翻译
#ESMO26 关于 #TemabA 在 #EGFR WT 和 #EGFR mut 既往接受治疗患者中的生物标志物疗效的新数据：
➡️ IHC MET+++
55 浏览 · 2 赞 · 0 转发 · 0 回复
会议摘要
2700RO按 Rapid oral 1: NSCLC, metastatic 对上
Improving prevention of moderate to severe dermatologic adverse events in EGFR-mutant advanced NSCLC treated with first-line (1L) subcutaneous (SC) amivantamab + lazertinib: First results from a new COCOON cohort
https://esmocongress.esmo.orgExtended circulating tumor DNA (ctDNA) sequencing to optimize the selection between anti-EGFR rechallenge and other later lines in patients with RAS/BRAF wild-type metastatic colorectal cancer
https://esmocongress.esmo.orgNCT06110663NCT06110663按 - **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy 对上
- **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
https://esmocongress.esmo.org来源：Giannis Mountzios · x.com